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Immunization has been the greatest strategy to prevent sickness and death associated with infectious diseases
[1]. So, vaccine technology has evolved to produce more immunogenic vaccines and to avoid the exposure to
disease-causing organisms during manufacturing and treatment [2]. Conversely, 2.5 million people are still dying
globally each year from vaccine-preventable diseases since the underuse of vaccines and lack vaccines against
non-well studied pathogens [2]. Only Cuba, Brazil and Argentina are listed as producers of vaccines against
infectious diseases such as yellow fever, leishmaniasis and rotavirus [3]. The roles of mentioned developing
countries are crucial because the produced vaccines are economically affordable which increase an increment
of vaccine coverage [3]. However, neglected communities are still susceptible to pathogens that are non-well
documented since they do not represent a high risk for public health. In Peru, several deaths are associated
with the infection of bacteria borne diseases and along to the last decades and preventative treatment is not yet
available. It has been developed some research aimed to develop a vaccine against Carrion’s disease in The
National Institute of Health from Peru. The employed procedure to produce the vaccine against Carrion’s
disease has not described the parameters used for the purification and characterization to obtain a highly pure
molecule for animal trial, consequently, the unexpected results could be obtained because the vaccine
candidate did not achieve the basic standard for the evaluation [4]. In conclusion, there are few the developing
Latin American countries involved in the vaccine technology field, and it is required to integrate effort among
global institutions to face diseases that affect neglected communities in developing countries.
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